The Ohio State University Corporate Engagement Office

Back to All Technologies

Methods of Pre-conditioning Patients for T-cell Therapy

College
College of Veterinary Medicine
Researchers
Kim, Sanggu
Licensing Manager
Dahlman, Jason "Jay"
(614)292-7945
dahlman.3@osu.edu

T2018-311

The Need

Recent advances in Chimeric Antigen Receptor (CAR) T-cell therapy have generated hope in treatment of diseases such as cancer and HIV/AIDS. Cytotoxic lymphodepletion preconditioning is a step included in most CAR T-cell therapies, where T-cells and “cytokine sink” cells are depleted to increase the effectiveness of CAR T-cells. However, current therapies have yielded inconsistent results among patients, including death in some preclinical trials. Currently, there is a need for a more effective lymphodepletion preconditioning therapy for use in CAR T-cell therapy.

The Technology

Dr. Sanggu Kim of The Ohio State University has developed a methodology to specifically ablate T-cells in the body. This treatment method utilizes CD3e immunotoxin (CD3e-IT), an anti-CD3e monoclonal antibody conjugated with diphtheria toxin (DT), to specifically ablate Tcells in the body. Results indicate that CD3e-IT specifically ablates CXCR5+ follicular T cell (Tfh) populations, which is a key target in CAR T-cell therapy for HIV-1 and follicular T-cell cancers.

Commercial Applications

  • Treatment of Cancer
  • Treatment of HIV/AIDS

Benefits/Advantages

  • Highly specific immunotoxin showing approximately 14- to 20- and 18- to 29-fold reduction rates for CD4+ T-cells and CD8+ T-cells
  • May provide a safer and more effective option for host preconditioning in CAR T-cell therapy